Tocqueville Asset Management L.P. Boosts Stock Position in GSK plc (NYSE:GSK)

Tocqueville Asset Management L.P. grew its stake in shares of GSK plc (NYSE:GSK - Free Report) by 23.6% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 46,900 shares of the pharmaceutical company's stock after purchasing an additional 8,950 shares during the quarter. Tocqueville Asset Management L.P.'s holdings in GSK were worth $1,586,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the stock. FMR LLC lifted its holdings in shares of GSK by 8.3% in the 3rd quarter. FMR LLC now owns 29,008,928 shares of the pharmaceutical company's stock worth $1,185,885,000 after buying an additional 2,224,345 shares during the period. Fisher Asset Management LLC raised its holdings in shares of GSK by 1.4% in the fourth quarter. Fisher Asset Management LLC now owns 18,836,797 shares of the pharmaceutical company's stock valued at $637,061,000 after acquiring an additional 259,867 shares in the last quarter. Primecap Management Co. CA lifted its stake in GSK by 2.4% in the third quarter. Primecap Management Co. CA now owns 14,853,755 shares of the pharmaceutical company's stock worth $607,222,000 after acquiring an additional 342,365 shares during the period. Mondrian Investment Partners LTD grew its holdings in GSK by 17.6% during the 4th quarter. Mondrian Investment Partners LTD now owns 5,838,384 shares of the pharmaceutical company's stock worth $205,920,000 after acquiring an additional 874,004 shares in the last quarter. Finally, Equity Investment Corp increased its position in GSK by 13.3% during the 4th quarter. Equity Investment Corp now owns 3,962,581 shares of the pharmaceutical company's stock valued at $134,014,000 after purchasing an additional 466,327 shares during the period. 15.74% of the stock is currently owned by institutional investors.

Remove Ads

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the stock. Morgan Stanley assumed coverage on shares of GSK in a research report on Wednesday, February 12th. They issued an "equal weight" rating for the company. StockNews.com upgraded GSK from a "buy" rating to a "strong-buy" rating in a report on Friday, February 7th. Seven research analysts have rated the stock with a hold rating and four have given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $43.25.

GSK Stock Down 1.7 %

GSK traded down $0.66 during trading on Monday, hitting $38.58. The stock had a trading volume of 4,066,672 shares, compared to its average volume of 4,344,593. The stock has a 50 day simple moving average of $36.66 and a two-hundred day simple moving average of $36.87. The company has a market capitalization of $79.86 billion, a PE ratio of 24.27, a PEG ratio of 1.12 and a beta of 0.58. The company has a debt-to-equity ratio of 1.12, a quick ratio of 0.52 and a current ratio of 0.78. GSK plc has a twelve month low of $31.72 and a twelve month high of $45.93.

GSK (NYSE:GSK - Get Free Report) last announced its earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.44 by $0.15. GSK had a return on equity of 48.59% and a net margin of 8.13%. On average, research analysts predict that GSK plc will post 4.14 earnings per share for the current year.

GSK Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, April 10th. Investors of record on Friday, February 21st will be given a $0.3932 dividend. This is a positive change from GSK's previous quarterly dividend of $0.39. This represents a $1.57 annualized dividend and a dividend yield of 4.08%. The ex-dividend date of this dividend is Friday, February 21st. GSK's dividend payout ratio (DPR) is presently 98.74%.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.